Rilonacept 220mg/vial Suppliers & Bulk Manufacturers
Available Forms: injection
Available Strengths: 220mg/vial
Originator reference: Arcalyst (USA/EU) (brand names belong to their owners and are shown only to identify the originator medicine)
Category: Immune Disorder
Rilonacept (Arcalyst) is a subcutaneous IL-1 inhibitor used to treat Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). It works by blocking interleukin-1, a protein that drives inflammation in these rare auto-inflammatory disorders. Rilonacept is available as an 80 mg/mL solution in pre-filled syringes.
Manufacture or export Rilonacept? List it or send an offer →
Product Description:
Rilonacept is an interleukin-1 trap: a fusion protein combining the extracellular domains of the IL-1 receptor and its accessory protein with the Fc portion of human IgG1. It acts as a decoy receptor, binding IL-1 beta — and also IL-1 alpha and the IL-1 receptor antagonist — with high affinity before they can reach cell-surface receptors. Its broader binding distinguishes it from antibodies specific to IL-1 beta alone.
It is used for cryopyrin-associated periodic syndromes, for deficiency of the IL-1 receptor antagonist, and for recurrent pericarditis, where it both treats the acute episode and reduces recurrence — an indication that expanded its market well beyond the rare autoinflammatory syndromes it was developed for. It is given by weekly subcutaneous injection after a loading dose. Because it blocks a central innate immune signal, serious infection risk rises, tuberculosis must be excluded before starting, and live vaccines are avoided. Injection site reactions are very common and lipid changes are reported.
Sourcing notes. Originator biologic, on patent, no biosimilar. Cold chain. Supplied as lyophilised powder for reconstitution. Weekly dosing makes annual cost high per patient; the pericarditis indication drives most current demand.
How Rilonacept is supplied today, and licensing ahead of patent expiry
Frequently Asked Questions
Arcalyst (Rilonacept) is developed and sold by Kiniksa Pharmaceuticals (developed by Regeneron). PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.
Related Products
Vamorolone
Strength:
40 mg/mL
Form: Oral suspension
Originator reference: Agamree (USA/EU)
View DetailsImiglucerase
Strength:
200 U/vial, 400 U/vial
Form: Injection
Originator reference: Cerezyme (USA/EU/ India)
View DetailsEtrasimod Arginine
Strength:
2 mg, 4 mg, 6 mg
Form: Tablets
Originator reference: Velsipity (USA)
View DetailsGuselkumab Injection
Strength:
100 mg/mL, 200 mg/2 mL (SC); 200 mg/20 mL (IV)
Form: Pre-filled syringe, pen (subcutaneous); vial (IV infusion)
Originator reference: Tremfya (Johnson & Johnson)
View DetailsRisankizumab Injection
Strength:
150 mg/mL (SC); 180 mg, 360 mg on-body injector; 600 mg/10 mL (IV)
Form: Pre-filled pen, syringe, on-body injector (SC); vial (IV)
Originator reference: Skyrizi (AbbVie)
View DetailsIxekizumab Injection
Strength:
80 mg/mL
Form: Pre-filled autoinjector, pre-filled syringe (subcutaneous)
Originator reference: Taltz (Eli Lilly)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit